Efficacy of Convection-based HDF Compare With Diffusion-based HD in Sepsis-associated AKI

Launched by RAMATHIBODI HOSPITAL · Jan 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for patients with acute kidney injury (AKI) that is caused by sepsis, a severe infection. The trial compares a method called online hemodiafiltration (OL-HDF), which is more advanced and may help remove larger harmful substances from the blood, to conventional hemodialysis (IHD), which is a standard treatment but may not be as effective in this situation. The main goal of the study is to see if OL-HDF can reduce levels of a specific inflammatory marker called C-reactive protein (CRP) better than IHD. Researchers will also look at other important outcomes, such as how long patients stay in the hospital and their overall survival after 30 days.

To be eligible for this trial, participants must be adults over 18 years old who are experiencing sepsis-related AKI and require kidney replacement therapy. However, individuals who are pregnant, have advanced kidney disease already receiving treatment, or are expected to die soon will not be included. Those who participate can expect to receive either OL-HDF or IHD while being closely monitored by healthcare professionals. It's important to note that OL-HDF requires specialized equipment and may be more complex and expensive than standard treatment. Ultimately, the choice of treatment will be tailored to each patient's specific condition and needs, in consultation with their healthcare team.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Sepsis-associated AKI requiring KRT
• • Age \>18 years old
• Exclusion Criteria:
• • Pregnancy
• • Patients with end stage kidney disease who are currently receiving kidney replacement therapy (chronic hemodialysis, peritoneal dialysis, kidney transplantation)
• • Patient who has refused to consent
• • Patient who dead or aim to dead within 24 hours after randomization
• • Patient who is receiving very high dose of vasopressor (norepinephrine \> 1 mcg/kg/min)
• • Patient who is receiving CRRT at first randomization